Medication info
Rinadipo Duo Tablets 2.5/500 mg (Linagliptin, Metformin)

Rinadipo Duo Tablets 2.5/500 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Biconvex oval film-coated tablet in bright yellow color
Packaging
30 tablets/bottle, 30 tablets/PTP [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202105928 · Approved 2021.08.12 · Insurance code 670609240

Summary

Main use
Improves glycemic control in type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose for each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. Patients not currently treated with metformin: For patients with no prior antidiabetic drug treatment whose glycemic control is inadequate with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment: This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment: This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improves glycemic control in type 2 diabetes

View approved original text

This medication is used to assist with blood sugar control in patients with type 2 diabetes along with diet control and exercise therapy. The combination of linagliptin and metformin helps effectively improve blood sugar levels. Therefore, it is useful for enhancing blood sugar management and alleviating diabetes symptoms.

How to take

Adult dose

The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose for each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. Patients not currently treated with metformin: For patients with no prior antidiabetic drug treatment whose glycemic control is inadequate with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment: This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment: This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains two components to help manage blood sugar. However, rare complications such as lactic acidosis may occur, which can pose severe risks due to excessive accumulation of lactic acid in the body. It is safer not to use this medication in patients with impaired kidney function, liver dysfunction, acute infections, severe dehydration, and decreased cardiac or pulmonary function. Women who are pregnant or nursing should also avoid this medication, and it is not recommended for children and adolescents. While taking this medication, symptoms of hypoglycemia may appear, so careful monitoring of blood sugar levels is necessary, especially when taken with other blood sugar-lowering agents. It is important to regularly check kidney function to confirm the safety of the medication, and if a sudden decline in kidney function is suspected, consult a doctor immediately. Acute pancreatitis or blistering skin conditions may develop; thus, if abdominal pain or skin abnormalities occur, stop taking the medication immediately and inform the healthcare provider. Vitamin B12 levels may decrease, so blood tests to check vitamin levels are recommended for prolonged use. This medication may interact with other drugs, so inform the doctor or pharmacist of any medications being taken. This medication should be temporarily discontinued before surgery or radiological examinations, and it can be resumed only after confirming that kidney function has returned to normal post-examination. Elderly patients often have reduced kidney function, so dosage adjustments and regular monitoring are necessary. This medication has not been sufficiently proven safe and effective for children, so it is advisable not to use it. Effects on driving or operating machinery are unknown, so it is important to assess one's response after taking the medication. In cases of overdose, immediate medical attention must be sought, particularly given the risk of lactic acidosis.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 130 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • metastasis to the liver
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • hearing loss
  • erectile dysfunction
  • goiter
  • kidney transplant failure
  • anemia
  • headache
  • sensory abnormalities
  • post-herpetic neuralgia
  • hemiparesis
  • syncope
  • drowsiness
  • chest discomfort
  • myasthenia
  • epistaxis
  • oropharyngeal pain
  • voice disorder
  • nasal hemorrhage
  • hypertension
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • diabetic neuropathy
  • dizziness
  • osteoarthritis
  • limb pain
  • pruritus
  • delirium
  • nocturia
  • dermatitis
  • hypercholesterolemia
  • increased blood creatinine
  • increased blood triglycerides
  • decreased hemoglobin
  • increased blood potassium
  • increased creatine kinase in the blood
  • increased blood glucose
  • increased blood creatinine
  • fever
  • facial edema
  • hyperthermia
  • back pain
  • flank pain
  • rotator cuff syndrome
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • angina
  • acute myocardial infarction
  • unstable angina
  • vocal cord polyp
  • stomatitis
  • mediastinitis
  • rhinitis
  • gingivitis
  • dyspepsia
  • gastritis
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastroesophageal reflux disease
  • increased blood triglycerides

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The recommended storage temperature is room temperature, between 1°C and 30°C. This will help maintain the medication's effectiveness and safety over time.

Appearance and packaging

Appearance

Biconvex oval film-coated tablet in bright yellow color

Package unit

30 tablets/bottle, 30 tablets/PTP [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.